MiR-186 Regulation of Twist1 and Ovarian Cancer Sensitivity to Cisplatin

Overview

Journal Oncogene

Specialties Molecular Biology
Oncology

Date 2015 Apr 14

PMID 25867064

Citations 88

Authors

X Zhu

H Shen

X Yin

L Long

C Xie

Y Liu

L Hui

X Lin

Y Fang

Y Cao

Y Xu

M Li

W Xu

Y Li

Affiliations

Soon will be listed here.

Abstract

Epithelial-mesenchymal transition (EMT) has an established role in promoting tumor progression and the acquisition of therapeutic resistance. Here, the EMT phenotype was detected in cisplatin-resistant ovarian cancer tissues and cell lines, and correlated with decreased miR-186 expression, increased Twist1 expression, chemoresistance and poor prognosis in epithelial ovarian cancer (EOC) patients. Introducing miR-186 into EOC cells led to a reduction in twist family bHLH transcription factor 1 (Twist1) expression along with morphological, functional and molecular changes consistent with mesenchymal-to-epithelial transition, G1 cell-cycle arrest and enhanced cell apoptosis, which consequently rendered the cells more sensitive to cisplatin in vitro and in vivo. Furthermore, luciferase reporter and rescue assay results showed that the EMT and drug resistance reversal in response to miR-186 was mediated by Twist1. Collectively, these findings implicate miR-186 as an attractive candidate for overcoming chemoresistance in ovarian cancer therapy.

Citing Articles

Exploring miRNA profile associated with cisplatin resistance in ovarian cancer cells.

Alghamian Y, Soukkarieh C, Aljapawe A, Murad H Biochem Biophys Rep. 2025; 41():101906.

PMID: 39830525 PMC: 11741906. DOI: 10.1016/j.bbrep.2024.101906.

Promising new drugs and therapeutic approaches for treatment of ovarian cancer-targeting the hallmarks of cancer.

Hillmann J, Maass N, Bauerschlag D, Florkemeier I BMC Med. 2025; 23(1):10.

PMID: 39762846 PMC: 11706140. DOI: 10.1186/s12916-024-03826-w.

Phenomics Demonstrates Cytokines Additive Induction of Epithelial to Mesenchymal Transition.

Boche A, Landras A, Morel M, Kellouche S, Carreiras F, Lambert A J Cell Physiol. 2024; 240(1):e31491.

PMID: 39565461 PMC: 11747948. DOI: 10.1002/jcp.31491.

Holotomography and atomic force microscopy: a powerful combination to enhance cancer, microbiology and nanotoxicology research.

Medina-Ramirez I, Macias-Diaz J, Masuoka-Ito D, Zapien J Discov Nano. 2024; 19(1):64.

PMID: 38594446 PMC: 11003950. DOI: 10.1186/s11671-024-04003-x.

Shake It Up Baby Now: The Changing Focus on TWIST1 and Epithelial to Mesenchymal Transition in Cancer and Other Diseases.

Mirjat D, Kashif M, Roberts C Int J Mol Sci. 2023; 24(24).

PMID: 38139368 PMC: 10743446. DOI: 10.3390/ijms242417539.

References

Konecny G, Wang C, Hamidi H, Winterhoff B, Kalli K, Dering J . Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. J Natl Cancer Inst. 2014; 106(10). PMC: 4271115. DOI: 10.1093/jnci/dju249. View

Baribeau S, Chaudhry P, Parent S, Asselin E . Resveratrol inhibits cisplatin-induced epithelial-to-mesenchymal transition in ovarian cancer cell lines. PLoS One. 2014; 9(1):e86987. PMC: 3899376. DOI: 10.1371/journal.pone.0086987. View

Puisieux A, Brabletz T, Caramel J . Oncogenic roles of EMT-inducing transcription factors. Nat Cell Biol. 2014; 16(6):488-94. DOI: 10.1038/ncb2976. View

Miow Q, Tan T, Ye J, Lau J, Yokomizo T, Thiery J . Epithelial-mesenchymal status renders differential responses to cisplatin in ovarian cancer. Oncogene. 2014; 34(15):1899-907. DOI: 10.1038/onc.2014.136. View

Yang A, Fan F, Camp E, Van Buren G, Liu W, Somcio R . Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res. 2006; 12(14 Pt 1):4147-53. DOI: 10.1158/1078-0432.CCR-06-0038. View

Chen J, Wang L, Matyunina L, Hill C, McDonald J . Overexpression of miR-429 induces mesenchymal-to-epithelial transition (MET) in metastatic ovarian cancer cells. Gynecol Oncol. 2011; 121(1):200-5. DOI: 10.1016/j.ygyno.2010.12.339. View

Parikh A, Lee C, Joseph P, Marchini S, Baccarini A, Kolev V . microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition. Nat Commun. 2014; 5:2977. PMC: 3896774. DOI: 10.1038/ncomms3977. View

Qin Q, Xu Y, He T, Qin C, Xu J . Normal and disease-related biological functions of Twist1 and underlying molecular mechanisms. Cell Res. 2011; 22(1):90-106. PMC: 3351934. DOI: 10.1038/cr.2011.144. View

Goeppert B, Schmezer P, Dutruel C, Oakes C, Renner M, Breinig M . Down-regulation of tumor suppressor A kinase anchor protein 12 in human hepatocarcinogenesis by epigenetic mechanisms. Hepatology. 2010; 52(6):2023-33. DOI: 10.1002/hep.23939. View

10.

Agarwal R, Kaye S . Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer. 2003; 3(7):502-16. DOI: 10.1038/nrc1123. View

11.

Nuti S, Mor G, Li P, Yin G . TWIST and ovarian cancer stem cells: implications for chemoresistance and metastasis. Oncotarget. 2014; 5(17):7260-71. PMC: 4202121. DOI: 10.18632/oncotarget.2428. View

12.

Kwok W, Ling M, Lee T, Lau T, Zhou C, Zhang X . Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Res. 2005; 65(12):5153-62. DOI: 10.1158/0008-5472.CAN-04-3785. View

13.

Wang Z, Li Y, Kong D, Banerjee S, Ahmad A, Azmi A . Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res. 2009; 69(6):2400-7. PMC: 2657919. DOI: 10.1158/0008-5472.CAN-08-4312. View

14.

Yang D, Sun Y, Hu L, Zheng H, Ji P, Pecot C . Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell. 2013; 23(2):186-99. PMC: 3603369. DOI: 10.1016/j.ccr.2012.12.020. View

15.

Myatt S, Wang J, Monteiro L, Christian M, Ho K, Fusi L . Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer. Cancer Res. 2009; 70(1):367-77. PMC: 2880714. DOI: 10.1158/0008-5472.CAN-09-1891. View

16.

Li J, Wood 3rd W, Becker K, Weeraratna A, Morin P . Gene expression response to cisplatin treatment in drug-sensitive and drug-resistant ovarian cancer cells. Oncogene. 2006; 26(20):2860-72. DOI: 10.1038/sj.onc.1210086. View

17.

. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474(7353):609-15. PMC: 3163504. DOI: 10.1038/nature10166. View

18.

Jia L, Zhang S, Ye Y, Li X, Mercado-Uribe I, Bast Jr R . Paclitaxel inhibits ovarian tumor growth by inducing epithelial cancer cells to benign fibroblast-like cells. Cancer Lett. 2012; 326(2):176-82. PMC: 3495569. DOI: 10.1016/j.canlet.2012.08.004. View

19.

Hiscox S, Jiang W, Obermeier K, Taylor K, Morgan L, Burmi R . Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation. Int J Cancer. 2005; 118(2):290-301. DOI: 10.1002/ijc.21355. View

20.

Ries J, Vairaktaris E, Agaimy A, Kintopp R, Baran C, Neukam F . miR-186, miR-3651 and miR-494: potential biomarkers for oral squamous cell carcinoma extracted from whole blood. Oncol Rep. 2014; 31(3):1429-36. DOI: 10.3892/or.2014.2983. View